var data={"title":"Chronic disseminated candidiasis (hepatosplenic candidiasis)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chronic disseminated candidiasis (hepatosplenic candidiasis)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/contributors\" class=\"contributor contributor_credentials\">Kieren A Marr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic disseminated candidiasis (also called hepatosplenic candidiasis) is seen almost entirely in patients with hematologic malignancies who have just recovered from an episode of neutropenia [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Very few cases, some of which were not well documented, have been reported in patients who did not have leukemia or neutropenia [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Clinical issues related to chronic disseminated candidiasis will be reviewed here. An overview of <em>Candida</em> infections as well as the clinical manifestations, diagnosis, and treatment of candidemia are presented separately. (See <a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">&quot;Overview of Candida infections&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of chronic disseminated candidiasis is not well understood, but this entity is thought to result from invasion of <em>Candida</em> species from the gastrointestinal tract into the bloodstream as a result of prolonged neutropenia and a breach in mucosal integrity. The portal system may receive the largest inoculum, and hence disease is prominent in the liver [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2,4\" class=\"abstract_t\">2,4</a>]. Evidence that the host inflammatory response plays an important role in the pathogenesis of this syndrome includes the histopathological picture of granulomatous (not suppurative) inflammation and the fact that symptoms and radiographic findings appear when the patient's neutrophils return to normal [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic disseminated candidiasis occurs almost exclusively in patients with acute leukemia but has been reported rarely in patients with lymphoma, aplastic anemia, and sarcoma [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>Chronic disseminated candidiasis is now seen less frequently because of the widespread use of antifungal agents for prophylaxis and early initiation of empiric antifungal therapy for neutropenic fevers in high-risk leukemic and hematopoietic cell transplant patients [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2,6\" class=\"abstract_t\">2,6</a>]. The potential magnitude of this effect was illustrated in an autopsy study performed between 1990 and 1994 in 329 hematopoietic cell transplant recipients [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/6\" class=\"abstract_t\">6</a>]. Patients who received <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> prophylaxis had, when compared with those who were not treated with fluconazole, significantly lower rates of <em>Candida</em> infections (8 versus 27 percent) and hepatic candidiasis (3 versus 16 percent). (See <a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">&quot;Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients&quot;</a> and <a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adults-with-hematologic-malignancies\" class=\"medical medical_review\">&quot;Prophylaxis of invasive fungal infections in adults with hematologic malignancies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Risk factors for chronic disseminated candidiasis include [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute leukemia</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged neutropenia (most commonly resulting from cytotoxic chemotherapy)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravascular catheters</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disruption of mucosal barriers</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administration of broad-spectrum antibiotics</p><p/><p>Patients who do not receive antifungal prophylaxis (eg, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>) are also likely to be at increased risk of chronic disseminated candidiasis.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of chronic disseminated candidiasis in which an organism has been identified have been due to <em>Candida albicans</em>; other species, such as <em>C. tropicalis</em>, <em>C. parapsilosis</em>, <em>C. glabrata</em>, and <em>C. krusei</em>, have occasionally been reported [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,3,7-9\" class=\"abstract_t\">1,3,7-9</a>]. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of candidemia in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1690258277\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'Susceptibility patterns'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Signs and symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The classic presentation of chronic disseminated candidiasis consists of persistent fever that is frequently high and spiking in a patient who was previously neutropenic and whose neutrophil count has returned to normal [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,10\" class=\"abstract_t\">1,10</a>]. Patients can be febrile for weeks if the diagnosis is not made in a timely manner, and, in one series, patients remained febrile for months [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=overview-of-neutropenic-fever-syndromes#H9533717\" class=\"medical medical_review\">&quot;Overview of neutropenic fever syndromes&quot;, section on 'Fungal pathogens'</a>.)</p><p>The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting, <span class=\"nowrap\">and/or</span> anorexia [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/8,11\" class=\"abstract_t\">8,11</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration, which may remain elevated for months [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2\" class=\"abstract_t\">2</a>]. In one study, 24 of 28 patients (86 percent) had a three- to fivefold elevation of alkaline phosphatase [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/11\" class=\"abstract_t\">11</a>]. Less common laboratory abnormalities include mildly elevated aspartate aminotransferase, alanine aminotransferase, and bilirubin, as well as leukocytosis [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>Some patients have a documented prior episode of candidemia (32 percent in a series of 28 patients) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/11\" class=\"abstract_t\">11</a>]. In others, it is assumed that the patient was candidemic during the period of neutropenia or that invasion occurred through the portal vasculature without corresponding positive venous blood cultures. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced computed tomography (CT) scanning, ultrasonography, magnetic resonance imaging (MRI), and positron emission tomography-CT during neutrophil recovery reveal characteristic multiple lesions, which represent microabscesses, in the liver, spleen, and sometimes the kidneys(<a href=\"image.htm?imageKey=ID%2F64691\" class=\"graphic graphic_diagnosticimage graphicRef64691 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,10,12-15\" class=\"abstract_t\">1,10,12-15</a>].</p><p>MRI is the most sensitive imaging technique for the diagnosis of chronic disseminated candidiasis, having sensitivity and specificity as high as 100 percent and 96 percent, respectively [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/12\" class=\"abstract_t\">12</a>]. Although the sensitivity of CT is lower than that of MRI (57 to 90 percent), it is used more frequently than MRI because it is less expensive and simpler to perform [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2,13,16\" class=\"abstract_t\">2,13,16</a>]. By comparison to MRI and CT, ultrasonography has a sensitivity of only 33 to 75 percent. If CT does not reveal the typical lesions in a patient in whom chronic disseminated candidiasis is suspected, an MRI should be performed.</p><p>The importance of neutrophils in the lesions of chronic disseminated candidiasis has been demonstrated by serial CT scanning, which may show disappearance of hepatic <span class=\"nowrap\">and/or</span> splenic lesions during neutropenia with reappearance after neutrophil recovery [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A definitive diagnosis can be established only by biopsy, which reveals multiple granulomas and, with special stains, yeasts and hyphal forms (<a href=\"image.htm?imageKey=ID%2F81112\" class=\"graphic graphic_picture graphicRef81112 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. Cultures of hepatic tissue obtained at biopsy are usually negative, particularly if antifungal therapy has been given; hence, a negative culture does not rule out the diagnosis.</p><p>Although biopsy is the gold standard, it often cannot be performed because the patient is thrombocytopenic. Fortunately, for almost every patient, the clinical, laboratory, and imaging characteristics are sufficiently specific that biopsy is not required.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mainstay of therapy for chronic disseminated candidiasis is antifungal therapy [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/18\" class=\"abstract_t\">18</a>]. Most experience has been with amphotericin B formulations or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, but, increasingly, echinocandins are used for this infection. This shift in antifungal therapy is related, in part, to increasing resistance to fluconazole.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Antifungal therapy</span></p><p class=\"headingAnchor\" id=\"H102395101\"><span class=\"h3\">Antifungal regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with the 2016 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis, which includes the following recommendations regarding the treatment of chronic disseminated candidiasis (<a href=\"image.htm?imageKey=ID%2F87678\" class=\"graphic graphic_table graphicRef87678 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14\" class=\"abstract_t\">14</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial therapy should be with a lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily) <strong>or</strong> an echinocandin for several weeks, followed by step-down therapy with an oral azole.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The recommended doses of the echinocandins are:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg loading dose, then 50 mg IV</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; 200 mg loading dose, then 100 mg IV daily</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> &ndash; 100 mg IV daily</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most patients, initial therapy should be followed by step-down therapy with oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg [6 <span class=\"nowrap\">mg/kg]</span> daily)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who have been shown to have a fluconazole-resistant isolate, such as patients who had a preceding candidemia with <em>C. glabrata</em> or <em>C. krusei</em>, we favor step-down therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>. However, there is minimal experience using these agents for this form of candidiasis, and they should only be used if the organism has been shown to be susceptible. Dosing is presented separately (see <a href=\"#H13\" class=\"local\">'Efficacy'</a> below and <a href=\"topic.htm?path=pharmacology-of-azoles#H23\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H24\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Posaconazole'</a>).</p><p/><p class=\"headingAnchor\" id=\"H3179835454\"><span class=\"h3\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon clinical experience, we suggest that antifungal therapy should be continued until there is resolution or calcification of the lesions on follow-up imaging (eg, contrast-enhanced computed tomography scan), which are usually obtained every two to three months [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14\" class=\"abstract_t\">14</a>]. Resolution of lesions occurs within six months in most, but not all, patients [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/8\" class=\"abstract_t\">8</a>]. As noted above, the hepatic <span class=\"nowrap\">and/or</span> splenic lesions can appear and disappear as the patient's neutrophil count rises and falls, respectively; such changes do not signify the failure or success of antifungal therapy [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/17\" class=\"abstract_t\">17</a>].</p><p>Therapy must be continued through periods of increased risk (eg, subsequent courses of chemotherapy, hematopoietic cell transplantation [HCT]) in order to prevent relapse [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14,19\" class=\"abstract_t\">14,19</a>]. If chemotherapy <span class=\"nowrap\">and/or</span> HCT are required, they should not be delayed in patients with chronic disseminated candidiasis [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Randomized trials evaluating the efficacy of antifungal drugs in the treatment of chronic disseminated candidiasis have not been performed. <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> have been studied most extensively for the treatment of chronic disseminated candidiasis [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/5,14,18\" class=\"abstract_t\">5,14,18</a>]. The following observations have been made based upon small open-label studies and case reports:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> has been variably successful [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1,8,10,19\" class=\"abstract_t\">1,8,10,19</a>]. Lipid formulations are probably more effective than amphotericin B deoxycholate [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2,20,21\" class=\"abstract_t\">2,20,21</a>], but some patients do not respond to either formulation [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 to 800 mg daily) has been effective for either step-down therapy (following a course of induction therapy with amphotericin B) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/8,10\" class=\"abstract_t\">8,10</a>] or primary therapy [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/23\" class=\"abstract_t\">23</a>], but it should be noted that these reports were published prior to more recent reports of increasing resistance to fluconazole.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individual case reports and series including a small number of patients document the success of echinocandins in treating chronic disseminated candidiasis [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/22,24-27\" class=\"abstract_t\">22,24-27</a>]. However, failures have also been reported [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/28\" class=\"abstract_t\">28</a>]. Echinocandins are especially useful for treatment of patients who have fluconazole-resistant species, such as <em>C. glabrata</em>. Smaller numbers of patients have been treated with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/29,30\" class=\"abstract_t\">29,30</a>].</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Splenectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Splenectomy, in combination with antifungal therapy, has occasionally been performed when the burden of abscesses is almost entirely in the spleen [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Adjuvant glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because chronic disseminated candidiasis occurs following neutrophil recovery in patients being treated for acute leukemia, it has been proposed that this entity may represent a form of immune reconstitution inflammatory syndrome (IRIS) [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p>It is common for patients to have persistent, high fevers as a single symptom in the setting of chronic disseminated candidiasis, despite appropriate antifungal therapy. There are several reports of patients with chronic disseminated candidiasis who have recalcitrant fever and in whom adjuvant glucocorticoid therapy has led to prompt resolution of systemic symptoms [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/5,18,29-32\" class=\"abstract_t\">5,18,29-32</a>]. A retrospective, multicenter study assessed the efficacy of oral glucocorticoids in 10 children and adults who had ongoing symptomatic probable or proven chronic disseminated candidiasis despite appropriate antifungal therapy [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/31\" class=\"abstract_t\">31</a>]. Patients who received a <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> equivalent of &ge;0.5 <span class=\"nowrap\">mg/kg</span> per day for at least three weeks had prompt resolution of fever and abdominal pain (median four to five days) and of the inflammatory response as measured by serum fibrinogen and C-reactive protein levels. However, the time to radiographic improvement (mean 106 days) was similar to that for historical controls. No relapses of candidiasis were observed.</p><p>Further studies will need to be performed in order to determine the safety and efficacy of adjuvant glucocorticoids for this indication. In patients with debilitating persistent fevers despite appropriate antifungal therapy, it is reasonable to add a glucocorticoid (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 0.5 to 1 <span class=\"nowrap\">mg/kg</span> orally daily) to the antifungal regimen for a few weeks (eg, one to two weeks), given as a tapering dose [<a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H1856686688\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Candidiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic disseminated candidiasis (also called hepatosplenic candidiasis) is seen almost entirely in patients who have hematologic malignancies and who have just recovered from an episode of neutropenia. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most cases in which an organism has been identified have been due to <em>Candida albicans </em>and sometimes<em> C. tropicalis.</em> Other species, such as <em>C. glabrata</em> and <em>C. krusei,</em> have occasionally been reported, especially in patients who are highly colonized <span class=\"nowrap\">and/or</span> have preceding candidemia. (See <a href=\"#H5\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The classic presentation of chronic disseminated candidiasis consists of persistent fever that is frequently high and spiking in a patient who was previously neutropenic and whose neutrophil count has returned to normal. The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting, <span class=\"nowrap\">and/or</span> anorexia. (See <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration. (See <a href=\"#H8\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Computed tomography (CT) scanning during neutrophil recovery reveals characteristic multiple lucencies in the liver, spleen, and sometimes the kidneys. (See <a href=\"#H9\" class=\"local\">'Imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A definitive diagnosis can be established only by biopsy, which reveals multiple granulomas and, with special stains, yeasts and hyphal forms (<a href=\"image.htm?imageKey=ID%2F81112\" class=\"graphic graphic_picture graphicRef81112 \">picture 1</a>). Cultures of hepatic tissue obtained at biopsy are usually negative, particularly if antifungal therapy has been given.</p><p/><p class=\"bulletIndent1\">Although biopsy is the gold standard, it often cannot be performed because the patient is thrombocytopenic. Fortunately, for almost every patient, the clinical, laboratory, and imaging characteristics are sufficiently specific that biopsy is not required. (See <a href=\"#H10\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For initial therapy, we recommend a lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously daily) <strong>or</strong> an echinocandin (<a href=\"image.htm?imageKey=ID%2F87678\" class=\"graphic graphic_table graphicRef87678 \">table 1</a>) (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). This should be continued for several weeks and followed by step-down therapy with an oral azole. (See <a href=\"#H102395101\" class=\"local\">'Antifungal regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The recommended doses of the echinocandins are:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg loading dose, then 50 mg intravenously (IV)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; 200 mg loading dose, then 100 mg IV daily</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> &ndash; 100 mg IV daily (see <a href=\"#H102395101\" class=\"local\">'Antifungal regimens'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following several weeks of induction therapy with a lipid formulation of amphotericin B or an echinocandin, we recommend transitioning to step-down therapy with an oral azole (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We give most patients oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg [6 <span class=\"nowrap\">mg/kg]</span> daily).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients who have been shown to have a fluconazole-resistant isolate, such as patients who had a preceding candidemia with <em>C. glabrata</em> or <em>C. krusei</em>, we give step-down therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>. However, there is minimal experience using these agents for this form of candidiasis, and they should only be used if the organism has been shown to be susceptible. (See <a href=\"#H102395101\" class=\"local\">'Antifungal regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antifungal therapy should be continued until there is resolution or calcification of the lesions on follow-up imaging (eg, contrast-enhanced computed tomography scan). Resolution of lesions occurs within six months in most, but not all, patients. The hepatic <span class=\"nowrap\">and/or</span> splenic lesions can appear and disappear as the patient's neutrophil count rises and falls, respectively; such changes do not signify the failure or success of antifungal therapy. (See <a href=\"#H3179835454\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Therapy must be continued through periods of increased risk (eg, subsequent courses of chemotherapy, hematopoietic cell transplantation) in order to prevent relapse. (See <a href=\"#H3179835454\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with chronic disseminated candidiasis with debilitating persistent fevers despite appropriate antifungal therapy, it is reasonable to add a glucocorticoid (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 0.5 to 1 <span class=\"nowrap\">mg/kg</span> orally daily) to the antifungal regimen for a few weeks, given as a tapering dose. (See <a href=\"#H17\" class=\"local\">'Adjuvant glucocorticoids'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/1\" class=\"nounderline abstract_t\">Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/2\" class=\"nounderline abstract_t\">Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14:721.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/3\" class=\"nounderline abstract_t\">Spindel SJ, Darouiche RO, Saeed ZA. Hepatosplenic candidiasis in non-neutropenic patients: a case report and literature survey. Int J Antimicrob Agents 1996; 7:149.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/4\" class=\"nounderline abstract_t\">Cole GT, Lynn KT, Seshan KR. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol 1990; 28:1828.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/5\" class=\"nounderline abstract_t\">Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses 2012; 55:e74.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/6\" class=\"nounderline abstract_t\">van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/7\" class=\"nounderline abstract_t\">Anttila VJ, Elonen E, Nordling S, et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997; 24:375.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/8\" class=\"nounderline abstract_t\">Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91:142.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/9\" class=\"nounderline abstract_t\">Ratip S, Odaba&#351;i Z, Karti S, et al. Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment. Clin Microbiol Infect 2002; 8:435.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/10\" class=\"nounderline abstract_t\">Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91:137.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/11\" class=\"nounderline abstract_t\">Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 2002; 87:535.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/12\" class=\"nounderline abstract_t\">Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 2005; 29:493.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/13\" class=\"nounderline abstract_t\">Anttila VJ, Lamminen AE, Bondestam S, et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56:82.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/14\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/15\" class=\"nounderline abstract_t\">Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011; 17:409.</a></li><li class=\"breakAll\">Samuels BI, Pagani JJ, Libshitz HI. Radiologic features of Candida infections. In: Candidiasis: Pathogenesis, Diagnosis and Treatment, Bodey GP (Ed), Raven Press, New York 1993. p.137.</li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/17\" class=\"nounderline abstract_t\">Pestalozzi BC, Krestin GP, Schanz U, et al. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997; 90:3858.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/18\" class=\"nounderline abstract_t\">De Castro N, Mazoyer E, Porcher R, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007. Clin Microbiol Infect 2012; 18:E185.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/19\" class=\"nounderline abstract_t\">Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76:2357.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/20\" class=\"nounderline abstract_t\">Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/21\" class=\"nounderline abstract_t\">Gokhale PC, Barapatre RJ, Advani SH, et al. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol 1993; 119:569.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/22\" class=\"nounderline abstract_t\">Sor&agrave; F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35:1135.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/23\" class=\"nounderline abstract_t\">de Pauw BE, Raemaekers JM, Donnelly JP, et al. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995; 70:83.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/24\" class=\"nounderline abstract_t\">Kontny U, Walsh TJ, Rossler J, et al. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer 2007; 49:360.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/25\" class=\"nounderline abstract_t\">H&uuml;bel K, Chemnitz J, Brochhagen HG, Cornely OA. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int J Hematol 2004; 79:289.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/26\" class=\"nounderline abstract_t\">Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/27\" class=\"nounderline abstract_t\">Poon LM, Chia HY, Tan LK, et al. Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature. Transpl Infect Dis 2009; 11:160.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/28\" class=\"nounderline abstract_t\">Vehreschild JJ, Kr&uuml;ger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006; 49 Suppl 1:42.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/29\" class=\"nounderline abstract_t\">Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/30\" class=\"nounderline abstract_t\">Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/31\" class=\"nounderline abstract_t\">Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46:696.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-disseminated-candidiasis-hepatosplenic-candidiasis/abstract/32\" class=\"nounderline abstract_t\">Chaussade H, Bastides F, Lissandre S, et al. Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. J Antimicrob Chemother 2012; 67:1493.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2425 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Risk factors</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">MICROBIOLOGY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Signs and symptoms</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Laboratory findings</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Imaging</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">TREATMENT</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Antifungal therapy</a><ul><li><a href=\"#H102395101\" id=\"outline-link-H102395101\">- Antifungal regimens</a></li><li><a href=\"#H3179835454\" id=\"outline-link-H3179835454\">- Duration of therapy</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Efficacy</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Splenectomy</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Adjuvant glucocorticoids</a></li></ul></li><li><a href=\"#H1856686688\" id=\"outline-link-H1856686688\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2425|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/64691\" class=\"graphic graphic_diagnosticimage\">- CT of hepatosplenic candidiasis</a></li></ul></li><li><div id=\"ID/2425|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/81112\" class=\"graphic graphic_picture\">- Hepatic candidiasis histology</a></li></ul></li><li><div id=\"ID/2425|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/87678\" class=\"graphic graphic_table\">- Treatment of chronic disseminated candidiasis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">Epidemiology and pathogenesis of candidemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">Overview of Candida infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neutropenic-fever-syndromes\" class=\"medical medical_review\">Overview of neutropenic fever syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adults-with-hematologic-malignancies\" class=\"medical medical_review\">Prophylaxis of invasive fungal infections in adults with hematologic malignancies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">Society guideline links: Candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Treatment of candidemia and invasive candidiasis in adults</a></li></ul></div></div>","javascript":null}